Effects of calpain inhibitors ALLM, ALLN, and calpastatin peptide on kinetic rates and duration of phases 1 and 2 of clot contraction
| . | ALLM (n = 8) . | ALLN (n = 8) . | Calpastatin peptide (n = 3) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No inhibitor . | Inhibitor . | Inhibition, % . | No inhibitor . | Inhibitor . | Inhibition, % . | No inhibitor . | Inhibitor . | Inhibition, % . | |
| Phase 1 kinetic rate, × 10−2 s−1 | 6.5 ± 4.2 | 5.1 ± 4.5 | 22 | 6.9 ± 4.4 | 4.8 ± 3.8 | 30 | 14.7 ± 5.5 | 12.6 ± 7.0 | 14 |
| Phase 1 duration, s | 290 ± 122 | 415 ± 147 | 43* | 289 ± 103 | 383 ± 86 | 32* | 158 ± 15 | 181 ± 23 | 15* |
| Phase 2 kinetic rate, × 10−2 s−1 | 5.3 ± 3.6 | 4.9 ± 3.0 | 8 | 5.3 ± 4.0 | 5.1 ± 3.5 | 4 | 4.8 ± 3.8 | 4.6 ± 3.7 | 4 |
| Phase 2 duration, s | 788 ± 122 | 638 ± 147 | 19* | 808 ± 103 | 731 ± 86 | 10* | 1027 ± 15 | 996 ± 23 | 3* |
| . | ALLM (n = 8) . | ALLN (n = 8) . | Calpastatin peptide (n = 3) . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No inhibitor . | Inhibitor . | Inhibition, % . | No inhibitor . | Inhibitor . | Inhibition, % . | No inhibitor . | Inhibitor . | Inhibition, % . | |
| Phase 1 kinetic rate, × 10−2 s−1 | 6.5 ± 4.2 | 5.1 ± 4.5 | 22 | 6.9 ± 4.4 | 4.8 ± 3.8 | 30 | 14.7 ± 5.5 | 12.6 ± 7.0 | 14 |
| Phase 1 duration, s | 290 ± 122 | 415 ± 147 | 43* | 289 ± 103 | 383 ± 86 | 32* | 158 ± 15 | 181 ± 23 | 15* |
| Phase 2 kinetic rate, × 10−2 s−1 | 5.3 ± 3.6 | 4.9 ± 3.0 | 8 | 5.3 ± 4.0 | 5.1 ± 3.5 | 4 | 4.8 ± 3.8 | 4.6 ± 3.7 | 4 |
| Phase 2 duration, s | 788 ± 122 | 638 ± 147 | 19* | 808 ± 103 | 731 ± 86 | 10* | 1027 ± 15 | 996 ± 23 | 3* |
Results are presented as mean ± standard deviation.
P < .05.